Sat, Jan 31, 2015, 7:39 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Seattle Genetics Inc. Message Board

  • redhot47fla redhot47fla Mar 4, 2013 2:09 PM Flag

    Highlights of SGEN's investor presentation - 3/4/2013

    Here are just a few highlights of today’s presentation by SGEN CEO Clay Siegall during the Cowen & Company 33rd Annual Health Care Conference in Boston (my Internet access cut out and I missed the middle third of the session):

    - Another hint that we don’t have to worry about dilution. Siegall: “Seattle Genetics is in a very good financial position that can fund our future development very strongly.”

    - SGEN now has 1,200 accounts for Adcetris. Since approval, no patient has been denied coverage by any insurance company for on-label use of Adcetris.

    - Several trials and partnerships are producing actual or anticipated "exciting" results. (In the past, his use of the word "exciting" has foreshadowed good things).

    - Make of this what you will, but he made many mentions of Takeda. One of them: “They’ve been a great partner so far, with much more to come.”

    That's all I have. I don't think he broke any new ground, but - again - I missed a chunk of this presentation.

    You can listen to the replay through a link on the SGEN investor page.

 
SGEN
31.16-0.340(-1.08%)Jan 30 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.